Automate Your Wheel Strategy on GILD
With Tiblio's Option Bot, you can configure your own wheel strategy including GILD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GILD
- Rev/Share 23.061
- Book/Share 15.3114
- PB 7.2249
- Debt/Equity 1.3022
- CurrentRatio 1.3693
- ROIC 0.1532
- MktCap 138213062300.0
- FreeCF/Share 7.9005
- PFCF 14.0403
- PE 23.2092
- Debt/Assets 0.4421
- DivYield 0.0279
- ROE 0.3171
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | GILD | Cantor Fitzgerald | -- | Overweight | -- | $125 | April 22, 2025 |
| Reiterated | GILD | Oppenheimer | -- | Outperform | $115 | $132 | March 4, 2025 |
| Upgrade | GILD | Deutsche Bank | Hold | Buy | -- | $120 | Feb. 18, 2025 |
| Upgrade | GILD | DZ Bank | Hold | Buy | -- | $108 | Feb. 13, 2025 |
| Upgrade | GILD | Morgan Stanley | Equal Weight | Overweight | $87 | $113 | Jan. 10, 2025 |
| Resumed | GILD | BofA Securities | -- | Buy | -- | $109 | Dec. 10, 2024 |
| Upgrade | GILD | Leerink Partners | Market Perform | Outperform | $74 | $96 | Oct. 21, 2024 |
| Initiation | GILD | Bernstein | -- | Outperform | -- | $105 | Oct. 17, 2024 |
| Upgrade | GILD | Wells Fargo | Equal Weight | Overweight | $78 | $100 | Oct. 7, 2024 |
News
Final Trades: Gilead Sciences, Amazon, Alphabet and KLA Corp.
Published: April 02, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term
Published: April 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
Published: April 01, 2025 by: CNBC
Sentiment: Negative
Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
Read More
GILD or AMGN: Which Is the Better Value Stock Right Now?
Published: April 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Amgen (AMGN). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Biopharma firms with foreign exposure face disruption as Trump's tariffs loom
Published: March 27, 2025 by: Proactive Investors
Sentiment: Negative
The biopharmaceutical industry is bracing for potential disruptions from proposed tariffs aimed at encouraging companies to move manufacturing operations back to the United States. This week, president Donald Trump suggested that tariffs could be implemented on pharma products made outside the US, with a particular focus on Ireland, where many biopharma companies benefit from favorable tax conditions.
Read More
Are Medical Stocks Lagging Gilead Sciences (GILD) This Year?
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how Gilead Sciences (GILD) and AngioDynamics (ANGO) have performed compared to their sector so far this year.
Read More
Gilead: Expansion Of Livdelzi For PBC Continues With European Marketing Approval
Published: March 23, 2025 by: Seeking Alpha
Sentiment: Positive
Gilead Sciences shows strong growth in its HIV and oncology franchises, with BIKTARVY and TRODELVY driving significant revenue increases in 2024. LIVDELZI's conditional approvals in the U.S. and Europe for PBC treatment could boost the Liver Disease portfolio, despite risks tied to confirmatory trials. SUNLENCA could become the first twice-yearly HIV prevention medication, pending regulatory approvals in the U.S. and Europe, potentially enhancing the HIV franchise.
Read More
Gilead Stock Falls on Report Trump Administration Wants to Cut HIV-Prevention Funding
Published: March 19, 2025 by: Barrons
Sentiment: Negative
Gilead Sciences is the maker of Biktarvy and Descovy, two drugs used to treat the virus.
Read More
Calls of the Day: Shake Shack, Starbucks, 3M, Gilead Sciences, Eli Lilly
Published: March 14, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee debate the latest Calls of the Day.
Read More
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Published: March 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Read More
Gilead Sciences, Inc. (GILD) Leerink Partners Global Healthcare Conference - (Transcript)
Published: March 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Gilead Sciences, Inc. (NASDAQ:GILD ) Leerink Partners Global Healthcare Conference Call March 11, 2025 10:40 AM ET Company Participants Cindy Perettie - Executive Vice President and Global Head, Kite Conference Call Participants Daina Graybosch - Leerink Partners Daina Graybosch I think we'll get started. Hi, everyone.
Read More
First Clinical Data for Gilead's Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
Published: March 11, 2025 by: Business Wire
Sentiment: Neutral
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company's injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention as pre-exposure prophylaxis (PrEP). The data were presented during an oral abstract session at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) and were also published today in T.
Read More
S&P 500 ETF's Worst Week Since September: 5 Top Stocks Poised to Rise
Published: March 10, 2025 by: Zacks Investment Research
Sentiment: Positive
These top-ranked stocks of the S&P 500 index have gained in the index's worst week since September. These stocks have more room to run.
Read More
Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?
Published: March 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Gilead Sciences (GILD) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.
Read More
3 Healthcare Stocks With Strong EPS Growth Potential to Buy in 2025
Published: March 07, 2025 by: Zacks Investment Research
Sentiment: Positive
GILD, OPCH and AVAH demonstrate resilience with impressive earnings surprise history.
Read More
Gilead Sciences, Inc. (GILD) TD Cowen 45th Annual Healthcare Conference (Transcript)
Published: March 04, 2025 by: Seeking Alpha
Sentiment: Neutral
Gilead Sciences, Inc. (NASDAQ:GILD ) TD Cowen 45th Annual Healthcare Conference March 4, 2025 11:10 AM ET Company Participants Johanna Mercier - Chief Commercial Officer Conference Call Participants Tyler Van Buren - TD Cowen Tyler Van Buren Well, good morning, everyone. Tyler Van Buren here, Senior Biotech Analyst at TD Cowen.
Read More
Pharmaceutical Stocks Hit New Highs Amid Market Volatility
Published: March 04, 2025 by: Zacks Investment Research
Sentiment: Negative
During this time of heightened market volatility, it pays to be invested in the right places.
Read More
Gilead Sciences sets aside $200 million to resolve HIV drug probe
Published: March 03, 2025 by: Reuters
Sentiment: Negative
Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into the drugmaker's promotional speakers program for HIV drugs.
Read More
Why Gilead Sciences Remains A Buy After A 40% Rally
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Positive
Two weeks ago, Gilead Sciences released financial results for the fourth quarter of 2024, which exceeded even my most optimistic expectations. The strong performance of its HIV franchise was driven by rising demand for Biktarvy, Descovy, and Sunlenca. So, sales of Biktarvy, the flagship of Gilead's HIV franchise, amounted to $3.77 billion, an increase of 21.4% year-on-year.
Read More
Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
Published: February 20, 2025 by: Business Wire
Sentiment: Neutral
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA. Seladelpar (an orphan designated product) is now approved and will provide an important treatment o.
Read More
GILD or VRTX: Which Is the Better Value Stock Right Now?
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Calls of the Day: Gilead Sciences and Merck
Published: February 18, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee debate the Calls of the Day in two biotech names.
Read More
Gilead Stock Rises 8% Post Q4 Earnings: Should You Buy or Sell?
Published: February 17, 2025 by: Zacks Investment Research
Sentiment: Positive
GILD's strong HIV portfolio should maintain momentum for the company. The guidance for 2025 is impressive.
Read More
Gilead Sciences (GILD) is a Top-Ranked Momentum Stock: Should You Buy?
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention
Published: February 12, 2025 by: Benzinga
Sentiment: Positive
Tuesday, Gilead Sciences Inc GILD reported fourth-quarter 2024 adjusted EPS of $1.90, beating the consensus of $1.70.
Read More
Gilead Sciences (GILD) is a Top-Ranked Value Stock: Should You Buy?
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Gilead Sciences, Inc. (GILD) Q4 2024 Earnings Call Transcript
Published: February 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Gilead Sciences, Inc. (NASDAQ:GILD ) Q4 2024 Earnings Conference Call February 11, 2025 4:30 PM ET Company Participants Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial Officer Dietmar Berger - Chief Medical Officer Andrew Dickinson - CFO Cindy Perettie - EVP, Kite Conference Call Participants Geoff Meacham - Citigroup Terrence Flynn - Morgan Stanley Tim Anderson - Bank of America Umer Raffat - Evercore ISI Michael Yee - Jefferies Daina Graybosch - Leerink Partners Mohit Bansal - Wells Fargo Brian Abrahams - RBC Capital Markets Tyler Van Buren - TD Cowen …
Read More
Gilead (GILD) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Markets Mixed on Powell Testimony, Q4 Earnings
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Negative
Tuesday, February 11, 2025 Market indexes were mixed today, after seeing all the majors in the red before the opening bell. The Dow closed up +123 points, +0.28%, while the S&P 500 squeaked by +2 points.
Read More
Gilead Sciences Beats Q4 EPS Forecast
Published: February 11, 2025 by: The Motley Fool
Sentiment: Positive
Gilead Sciences (GILD 0.69%), a major player in the biotechnology sector, reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 11, that topped analysts' consensus estimates. Adjusted earnings per share of $1.90 came in well ahead of the estimated $1.74.
Read More
About Gilead Sciences, Inc. (GILD)
- IPO Date 1992-01-22
- Website https://www.gilead.com
- Industry Drug Manufacturers - General
- CEO Mr. Daniel P. O'Day
- Employees 17600